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Male Turner syndrome 
Pseudo-Turner syndrome 
Inheritance 
Noonan syndrome is an autosomal dominant disorder. 
Rare cases with parental consanguinity have been 
described, but it is not clear that these represent true 
instances of autosomal recessive  
inheritance. Like many autosomal dominant disorders, 
a significant, but not precisely determined, percentage 
of cases represent de novo mutagenesis. The prevalence 
of Noonan syndrome has not been determined 
accurately to date. Most authors cite the figure of 1 in 
1,000-2,500 live births. However, that estimate wasnot 
based on a population study. Fetal loss occurs for 
Noonan syndrome so disease incidence is higher than 
prevalence, but no estimate of the magnitude of this
discrepancy is available. 
Clinics 
Phenotype and clinics 
Noonan syndrome is a clinically variable 
developmental disorder defined by short stature, facial 
dysmorphism and a wide spectrum of congenital heart 
defects. The distinctive facial features consist of a 
broad forehead, hypertelorism, down-slanting palpebral 
fissures, ptosis, high-arched palate and low-set, 
posteriorly rotated ears. Cardiovascular abnormalities, 
primarily pulmonic stenosis and hypertrophic 
cardiomyopathy, are present in up to 85% of affected 
individuals. Additional relatively frequent features are  
multiple skeletal defects (spine and chest), webbed 
neck, mental retardation, cryptorchidism and bleeding 
diathesis. 
Neoplastic risk 
Children with Noonan syndrome are predisposed to 
malignancies, juvenile myelomonocytic leukemia 
(JMML) most commonly. JMML, formerly termed 
juvenile chronic myeloid leukemia or chronic 
myelomonocytic leukemia, is a myeloproliferative/ 
myelodysplastic disorder of childhood characterized by 
excessive proliferation of immature and mature 
myelomonocytic cells that originate from a pluripotent 
stem cell. In childhood, JMML accounts for 
approximately 30% of cases of myelodysplastic and 
myeloproliferative syndromes and 2% of leukemias. It 
typically presents in infancy and early childhood, and is 
often lethal. Recent studies have provided strong 
evidence that hypersensitivity to granulocyte-
macrophage colony-stimulating factor (GM-CSF), due 
to a selective inability to down-regulate the 
RAS/MAPK cascade, plays a central role in the clonal 
cell growth characteristic of JMML. In approximately 
15-30% of JMML cases, the pathological activation of 
the RAS/MAPK cascade results from oncogenic NRAS 
or KRAS2 mutations that specifically affect GTP 
hydrolysis, leading to the accumulation of RAS in the 
GTP-bound active conformation. JMML has been 
reported in children with neurofibromatosis type 1 
(NF1), an autosomal dominant disorder resulting from 
germline loss-of-function mutations of the NF1 tumor 
suppressor gene. In children with NF1 and JMML, the 
proliferative advantage of the leukemic cells results 
from a second hit, the somatic loss or inactivation of 
the normal NF1 allele.  










Clinical features in Noonan syndrome. (A) Prenatal echography showing nuchal cystic hygroma; (B) dysmorphic facial features; (C) 
pectus deformities and cubitus valgus; (D) webbed neck; (E) schematic representation of major cardiac defects: 1, pulmonic stenosis; 2, 
hypertrophic cardiomyopathy; 3, atrial septal defects; 4, ventricular septal defects; 5, patent ductus arteriosus. (Figures kindly provided by 
G. Zampino, MD, Università Cattolica del Sacro Cuore, Rome, Italy). 
 
Since the NF1 gene product, neurofibromin, is a 
negative modulator of RAS function, this loss is 
associated with RAS hyperactivity. Remarkably, 
deregulated RAS function appears to be restricted to 
GM-CSF signaling in hematopoietic cells. More 
recently, somatic activating mutations in the PTPN11 
gene, which encodes the protein tyrosine phosphatase 
(PTP) SHP-2, have been documented in approximately 
35% of cases with JMML.  
Mutations in the PTPN11, RAS and NF1 genes are 
largely mutually exclusive in JMML, and their 
combined prevalence accounts for approximately 85% 
of cases. Acute lymphoblastic leukemia and solid 
tumors, particularly neuroblastoma and 
rhabdomyosarcoma, have also been documented with a 
relatively higher prevalence respect to the general 
population. 
Evolution 
In children with Noonan syndrome JMML may regress 
without treatment or follow an aggressive clinical 
course. By contrast, cases of JMML that arise in 
children without Noonan syndrome have a poor 




A significant percentage of Noonan syndrome cases 
arise from de novo PTPN11 mutations. Among 
fourteen informative families, each consisting of an
affected individual heterozygous for a PTPN11 
mutation and unaffected parents, the paternal origin of 
mutation has been demonstrated in all cases.  
Consistent with this finding, advanced paternal age was 
noted among fathers of sporadic Noonan syndrome 
cases, compared with fathers of the reference 
population.  
Moreover, when a parent is affected with Noonan 
syndrome and harbors a PTPN11 mutation, a sex-ratio 
bias is operative for offspring who inherit the defect. 
This bias favors males by a factor of 2:1. The avail ble 
data point to this bias being attributable to sex-specific 
developmental effects of PTPN11 mutations that favor 
survival of affected male embryos compared to femal 
ones. 
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Genes involved and proteins 
PTPN11 (Protein tyrosine phosphatase, 
non-receptor type, 11) 
Location 
12q24.1 
Centromere - FLJ34154 - RPL6 - PTPN11 - RPH3A - 
OAS1 – telomere. 
DNA/RNA 
Description: The PTPN11 gene counts 16 exons. Exon 
1 contains the 5'-UTR and the translation initiation 
ATG, and a few additional codons. Exon 15 contains 
the stop codon and exon 16 contains a major portion of 
the 3'-UTR. Other features of the PTPN11 gene, such 
as the promoter region and enhancer elements have not 
been delineated. 
Transcription: A 7.0-kb transcript is detected in several 
tissues (heart, brain, lung, liver, skeletal muscle, 
kidney, and pancreas) with highest steady-state levls 
in heart and skeletal muscle. The predominant human 
PTPN11 mRNA contains an open reading frame of 
1,779 bases, resulting in a predicted protein of 593 
amino acid residues. 
Pseudogene: A number of speudogenes, sharing more 
than 92% nucleotide identity with PTPN11 cDNA 
(including the untranslated regions), have been 
documented in the human genome. All the pseudogenes 
harbour frameshift mutations and multiple stop codons. 
Three of the five pseudogenes are likely to be 
expressed but with distinct tissue distribution and 
expression level. 
Protein 
Description: SHP-2 is a member of a small subfamily 
of cytoplasmic Src homology 2 (SH2) domain-
containing protein tyrosine phosphatases. The amino-
terminal SH2 (N-SH2 and C-SH2) domains selectively 
bind to short amino acid motifs containing a 
phosphotyrosyl residue and promote SHP-2 association 
with cell surface receptors, cell adhesion molecules and 
scaffolding adapters. Crystallographic data indicate that 
the N-SH2  
domain also interacts with the PTP domain using a 
separate site. As these subdomains show negative 
cooperativity, the N-SH2 domain functions as an 
intramolecular switch controlling SHP-2 catalytic 
activation. Specifically, the N-SH2 domain interacts 
with the PTP domain basally, blocking the catalytic 
site. Binding of the N-SH2 phosphopeptide-binding site
to the phosphotyrosyl ligand promotes a 
conformational change of the domain that weakens the 
auto-inhibiting intramolecular interaction, making the 
catalytic site available to substrate, thereby activ ting 
the phosphatase. 
Expression: Widely expressed in both embryonic and 
adult tissues. 
Localisation: Cytoplasmic. It binds to activated cell 
surface receptors, cell adhesion molecules and 
scaffolding adapters. Phosphorylation of two tyrosine 
residues at the C-terminus by activated tyrosine kiase 
receptors creates binding sites for other SH2 domain-
containing signal transducers. 
Function: SHP-2 functions as a intracellular signal 
transducer.  It positively modulates signal flow in most 
circumstances, but can also function as negative 
regulator depending upon its binding partner and 
interactions with downstream signaling networks. SHP-
2 positively controls the activation of the RAS/MAPK 
cascade induced by several growth factors, and 
negatively regulates JAK/STAT signaling. In most 
cases, SHP-2's function in intracellular signaling 
appears to be immediately proximal to activated 
receptors and upstream to RAS. The mechanisms of 
SHP-2's action and its physiological substrates are still 
poorly defined. However, both membrane translocation 
and PTPase activity are required for SHP-2 function. 
SHP-2 is required during development. Embryos 
nullizygous for Shp-2 have defects in gastrulation and 
mesodermal patterning resulting in severe 
abnormalities in axial and paraxial mesodermal 
structures. Shp-2 function is also required for 
development of terminal and skeletal structures, 
semilunar valvulogenesis in the heart, and 
hematopoiesis. 
 
The PTPN11 gene and SHP-2 domain characterization. The coding exons are shown as numbered filled boxes. The functional domains 
of the protein, comprising two amino-terminal, tandemly arranged SH2 domains (N-SH2 and C-SH2) followed by a protein tyrosine 
phosphatase (PTP) domain, are shown below.  Numbers below the domain structure indicate the amino-acid boundaries of those 
domains. 










Figure 3: Three-dimensional structure of SHP-2 in its catalytically inactive conformation, as determined by Hof and co-workers. Residues 
involved in catalysis are shown (space fill). 
Figure 4: Location of SHP-2 mutated residues in human disease. (A) Noonan syndrome and LEOPARD syndrome (germ-line origin; 
N=224); (B) Noonan syndrome with juvenile myelomonocytic leukemia (germ-line origin; N=11); (C) hematologic malignancies, including 
juvenile myelomonocytic leukemia, acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes and chronic 
myelomonocytic leukemia (somatic origin; N=97). The pictures show the Ca trace of SHP-2 in its catalytically inactive conformation. 
Affected residues are indicated with their side chains as black sticks. 
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Homology: PTPN6 (protein tyrosine phosphatase, non-
receptor type, 6) previously known as SHP1 or SHP-1 
(Src homology 2 domain-containing protein tyrosine 
phosphatase, 1). 
Mutations 
Studies reported PTPN11 mutation detection rates 
ranging between 33% to 60%. Differences in inclusion 
criteria stringency and recruiting strategies are lik ly to 
responsible for such variable mutation detection rate. It 
should also be emphasized that the mutation prevalence 
detected in any Noonan syndrome cohort is sensitive to 
its composition in terms of relative abundance of 
sporadic and familial cases, as PTPN11 mutations 
appear to be more prevalent among families 
transmitting the trait compared to sporadic cases. With 
those issues stipulated, the contribution of PTPN11 
mutations to the etiology of Noonan syndrome appears 
to be approximately 50%. 
A statistically significant association with pulmonary 
valve stenosis and lower incidence of hypertrophic 
cardiomyopathy was found among the group with 
PTPN11 mutations. Overall, a large percentage of 
PTPN11 mutation-negative individuals tended to 
exhibit fewer or mild clinical features of NS, even 
though approximately half of the Noonan syndrome 
patients without a PTPN11 mutation appeared 
clinically indistinguishable from typical PTPN11 
mutation-positive patients. 
Germinal: The vast majority of mutations affect 
residues residing at or close to the interface betwe n 
the N-SH2 and PTP domains. Increasing evidence 
supports that a number of Noonan syndrome-causative 
mutations promote SHP-2 gain-of-function by 
destabilizing the catalytically inactive conformation of 
the protein, and prolong signal flux through the 
RAS/MAPK pathway in a ligand-dependent manner. 
Selection: 124A>G (T42A), 182A>G (D61G), 184T>G 
(Y62D), 188A>G (Y63C), 214G>T (A72S), 215C>G 
(A72G), 218C>T (T73I), 228G>T, C (E76D), 236A>G 
(N79R), 317A>C (D106A), 922A>G (N308D). 
Two specific missense mutations (836A>G, Y279C; 
1403C>T, T468M) have been identified to recur in 
LEOPARD syndrome, a developmental disorder 
closely related to Noonan syndrome. A mouse model 
bearing the NS-causative Asp61Gly mutation in the 
Ptpn11 gene has been recently generated and 
characterized. The Ptpn11D61G/ D61G genotype is 
embryonic lethal. At day E13.5, these embryos are 
grossly edematous and hemorrhagic, and have diffuse 
liver necrosis. A number of severe cardiac defects are 
also observed. Heterozygous embryos exhibit cardiac 
defects, proportionate growth failure and perturbed 
craniofacial development. Hematologic anomalies 
include a mild myeloproliferative disease. 
Ptpn11D61G/+ embryonic fibroblasts are characterized 
by a three-fold increased Shp-2 activity and increased 
association of Shp-2 with Gab1 after stimulation with 
EGF. Cell culture and whole embryo studies reveal th t
increased RAS/MAPK signaling is variably present, 
appearing to be cell-context specific. 
Somatic: Somatic activating mutations in PTPN11 have 
been documented in a heterogeneous group of 
hematologic malignancies and pre-leukemic disorders, 
and rarely in certain solid tumors. 
Selection: 181G>T (D61Y), 182A>T (D61V), 205G>A 
(E69K), 214G>A (A72T), 215C>T (A72V), 226G>A 
(E76K), 226G>C (E76Q), 227A>T (E76V), 227A>G 
(E76G), 227A>C (E76A), 1471C>T (P491S), 
1472C>T (P491L), 1504T>C (S502P), 1504T>G 
(S502A), 1520C>A (T507K), 1528C>A (Q510K). 
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